The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Cisplatin, epirubicin, capecitabine, and gemcitabine (PEXG) as first-line treatment in metastatic or unresectable pancreatic cancer: Active and well tolerated?
Gareth Rivalland
No relevant relationships to disclose
Benjamin James Lawrence
No relevant relationships to disclose
Soizick Jeanne Lynette Mesnage
No relevant relationships to disclose
Jane Reeve
No relevant relationships to disclose
Michael P. N. Findlay
No relevant relationships to disclose